Analysis of contraindications and unsuitable groups for tazetostat (Daveco)

Tazemetostat (Tazemetostat) is a new type of EZH2 inhibitor, mainly used to treat some relapsed or refractory epithelioid sarcoma (epithelioid sarcoma) and follicular lymphoma (follicular lymphoma) and other tumor types under investigation. It inhibits the growth of tumor cells and induces apoptosis by inhibiting EZH2 gene mutations or dependent pathways. As a targeted drug, it shows high specificity and certain tolerance in clinical application, but there are still some contraindications and unsuitability for the population, and patients and doctors need to conduct a comprehensive evaluation before taking the drug.

1. Main contraindications of tazetostat

1.Contraindicated for those who are allergic to drug ingredients

Tazerestat preparations contain specific active ingredients and excipients. If the patient has a history of severe allergy to the active ingredients or other excipients, it may cause rash, dyspnea or even anaphylactic shock, so it is clearly contraindicated.

2.Contraindicated for pregnant women

Existing research shows that EZH2 inhibitors may cause potential risks to fetal development, such as teratogenesis or miscarriage. Adverse effects of the drug on embryonic development have been observed in animal experiments, so its use by pregnant women is prohibited.

3.Contraindicated for lactating women

Although there is insufficient evidence to determine whether tazerestat is excreted in breast milk, breastfeeding women should avoid using this drug due to the possible adverse effects on the infant.

4.Contraindicated in patients with severe liver dysfunction

Tazerestat is mainly metabolized by the liver. Patients with severe liver damage may cause a decrease in drug clearance and increase accumulation in the body, thus aggravating toxic reactions. Therefore, it is contraindicated in patients with Child-Pugh C liver dysfunction.

2. People who are not suitable or need to use with caution

1.Patients with moderate to severe liver function impairment

Although patients with mild to moderate hepatic impairment are not absolutely contraindicated, they need to carefully adjust the dose and closely monitor liver function indicators, such as transaminases (ALT/AST), bilirubin, etc. If liver function deteriorates significantly, treatment should be suspended or discontinued.

2.Patients with renal insufficiency

Tazerestat is partially excreted by the kidneys, and patients with severe renal impairment may experience elevated drug plasma concentrations, thereby increasing the risk of adverse reactions. Clinically, the dose should be adjusted individually based on the patient's renal function.

3.Patients taking concomitant use of strongCYP3A inhibitors or inducers

Tazerestat is mainly metabolized by CYP3Aenzyme. If patients take strong CYP3A inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampicin, carbamazepine) at the same time, the blood concentration of the drug may be significantly affected, resulting in reduced efficacy or increased toxicity. Therefore, these patients need strict drug interaction evaluation to avoid combination or adjustment of medications.

4.Those who have a bleeding tendency or are receiving anticoagulant therapy

Tazetostat may affect platelet count and function and increase the risk of bleeding. If the patient is receiving anticoagulant therapy such as warfarin or heparin, coagulation function indicators should be closely monitored and the anticoagulant dose should be adjusted or treatment suspended if necessary.

3. Safety precautions in clinical application

1.Monitor blood routine regularly

Tazerestat may cause anemia, neutropenia or thrombocytopenia, so patients need to have regular blood tests during treatment to detect hematological toxicity in a timely manner and intervene.

2.Pay attention to liver and kidney function

During long-term medication, liver and kidney function are important factors affecting drug metabolism and clearance, and indicators such as ALT, AST, and creatinine clearance need to be monitored regularly. If significant abnormalities are found, dose reduction or discontinuation should be considered.

3. Fertility and contraceptive guidance

Male and female patients should take effective contraceptive measures during treatment and for at least 6 months after treatment to avoid potential damage to offspring caused by the drug.

4.Long-term safety monitoring

Although tazerestat is generally well tolerated, due to its short time on the market, safety data for long-term application are limited, and experience needs to be accumulated in practical applications. Doctors need to conduct risk assessment and follow-up based on the patient's individual situation.

Tazestat as a new generation EZH2Inhibitors have shown good efficacy and certain safety in the treatment of some malignant tumors, but not all patients are suitable for use. Its main contraindications include drug allergies, pregnant and lactating women, severe liver dysfunction, etc. Patients with liver and kidney dysfunction, patients who are taking CYP3A related drugs, or patients with bleeding risks need to be carefully evaluated. During clinical application, monitoring of blood routine, liver and kidney function, and drug interactions must be strengthened, and dosage adjustments must be made based on individualized conditions. Only by properly identifying unsuitable groups and implementing risk prevention and control can we maximize the therapeutic value of tazetostat, reduce the incidence of adverse reactions, and improve patient survival benefits.

Reference materials:https://www.drugs.com/